
VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.
The FDA has accepted Nanoscope's BLA for sonpiretigene isteparvovec in retinitis pigmentosa, backed by RESTORE and REMAIN trial data.
The US Food and Drug Administration has




